Oncternal Therapeutics Stock Buy Hold or Sell Recommendation
| ONCT Stock | USD 1.14 0.02 1.72% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Oncternal Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Oncternal Therapeutics given historical horizon and risk tolerance towards Oncternal Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Oncternal Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Oncternal Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide. Note, we conduct extensive research on individual companies such as Oncternal and provide practical buy, sell, or hold advice based on investors' constraints. Oncternal Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Oncternal |
Execute Oncternal Therapeutics Buy or Sell Advice
The Oncternal recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Oncternal Therapeutics. Macroaxis does not own or have any residual interests in Oncternal Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oncternal Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Oncternal Therapeutics Trading Alerts and Improvement Suggestions
| Oncternal Therapeutics generated a negative expected return over the last 90 days | |
| Oncternal Therapeutics has high historical volatility and very poor performance | |
| Oncternal Therapeutics may become a speculative penny stock | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oncternal Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Oncternal announces workforce reduction, executive changes |
Oncternal Therapeutics Returns Distribution Density
The distribution of Oncternal Therapeutics' historical returns is an attempt to chart the uncertainty of Oncternal Therapeutics' future price movements. The chart of the probability distribution of Oncternal Therapeutics daily returns describes the distribution of returns around its average expected value. We use Oncternal Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oncternal Therapeutics returns is essential to provide solid investment advice for Oncternal Therapeutics.
| Mean Return | -1.33 | Value At Risk | -14.12 | Potential Upside | 11.49 | Standard Deviation | 11.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oncternal Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oncternal Stock Institutional Investors
The Oncternal Therapeutics' institutional investors refer to entities that pool money to purchase Oncternal Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Wells Fargo & Co | 2024-06-30 | 300 | North Star Investment Management Corp | 2024-09-30 | 250 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 182 | Advisor Group Holdings, Inc. | 2024-06-30 | 150 | U.s. Bancorp | 2024-06-30 | 100.0 | Ubs Group Ag | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 22.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 15.0 | Lindbrook Capital, Llc | 2024-06-30 | 15.0 | Vanguard Group Inc | 2024-09-30 | 139.9 K | Millennium Management Llc | 2024-06-30 | 102.9 K |
Oncternal Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oncternal Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oncternal Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oncternal stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.28 | |
β | Beta against Dow Jones | -0.62 | |
σ | Overall volatility | 11.39 | |
Ir | Information ratio | -0.13 |
Oncternal Therapeutics Volatility Alert
Oncternal Therapeutics is displaying above-average volatility over the selected time horizon. Oncternal Therapeutics is a potential penny stock. Although Oncternal Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Oncternal Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Oncternal instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Oncternal Therapeutics Fundamentals Vs Peers
Comparing Oncternal Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oncternal Therapeutics' direct or indirect competition across all of the common fundamentals between Oncternal Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oncternal Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oncternal Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oncternal Therapeutics to competition |
| Fundamentals | Oncternal Therapeutics | Peer Average |
| Return On Equity | -1.5 | -0.31 |
| Return On Asset | -0.76 | -0.14 |
| Operating Margin | (17.57) % | (5.51) % |
| Current Valuation | (11.01 M) | 16.62 B |
| Shares Outstanding | 2.96 M | 571.82 M |
| Shares Owned By Insiders | 9.23 % | 10.09 % |
| Shares Owned By Institutions | 12.07 % | 39.21 % |
| Number Of Shares Shorted | 45.35 K | 4.71 M |
| Price To Earning | (37.77) X | 28.72 X |
| Price To Book | 0.37 X | 9.51 X |
| Price To Sales | 1.59 X | 11.42 X |
| Revenue | 785 K | 9.43 B |
| Gross Profit | (31.49 M) | 27.38 B |
| EBITDA | 2.23 M | 3.9 B |
| Net Income | (39.48 M) | 570.98 M |
| Cash And Equivalents | 78.9 M | 2.7 B |
| Cash Per Share | 1.48 X | 5.01 X |
| Total Debt | 318 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 10.78 X | 2.16 X |
| Book Value Per Share | 3.09 X | 1.93 K |
| Cash Flow From Operations | (32.16 M) | 971.22 M |
| Short Ratio | 0.36 X | 4.00 X |
| Earnings Per Share | (11.69) X | 3.12 X |
| Target Price | 2.0 | |
| Number Of Employees | 27 | 18.84 K |
| Beta | 1.33 | -0.15 |
| Market Capitalization | 3.43 M | 19.03 B |
| Total Asset | 36.73 M | 29.47 B |
| Retained Earnings | (197.78 M) | 9.33 B |
| Working Capital | 30.86 M | 1.48 B |
| Current Asset | 27.27 M | 9.34 B |
| Current Liabilities | 6.3 M | 7.9 B |
Note: Acquisition by Desimone Jill of 2200 shares of Oncternal Therapeutics at 8.1 subject to Rule 16b-3 [view details]
Oncternal Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oncternal . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1138.97 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 1.13 | |||
| Day Typical Price | 1.13 | |||
| Period Momentum Indicator | (0.02) |
About Oncternal Therapeutics Buy or Sell Advice
When is the right time to buy or sell Oncternal Therapeutics? Buying financial instruments such as Oncternal Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oncternal Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.